Novelties in the field of antimicrobial compounds for the treatment of lower respiratory tract infections

Pulm Pharmacol Ther. 2003;16(3):131-45. doi: 10.1016/S1094-5539(03)00050-6.

Abstract

Emergence of antimicrobial resistance is a growing problem and a public health threat. New drugs must be designed with emerging needs in mind: specific resistant and hard-to-treat organisms. But the difficulty to find real new drugs is a major problem. Only the oxazolidinones, the cationic peptides and the lipopeptide antibiotics can be truly regarded as structurally novel drugs, although the peptide deformylase inhibitors and, possibly, the pleuromutilins can be considered a potential advancement in the field. Obviously, these antibiotics must be reserved only to cases of documented ineffectiveness of the common antimicrobial agents.

Publication types

  • Review

MeSH terms

  • Acetamides* / pharmacokinetics
  • Acetamides* / pharmacology
  • Acetamides* / therapeutic use
  • Amidohydrolases*
  • Aminopeptidases / antagonists & inhibitors
  • Anti-Bacterial Agents* / pharmacokinetics
  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Area Under Curve
  • Bacteria / drug effects
  • Bacteria / isolation & purification
  • Economics, Pharmaceutical
  • Half-Life
  • Humans
  • Linezolid
  • Microbial Sensitivity Tests
  • Oxazolidinones* / adverse effects
  • Oxazolidinones* / economics
  • Oxazolidinones* / pharmacokinetics
  • Oxazolidinones* / pharmacology
  • Oxazolidinones* / therapeutic use
  • Respiratory Tract Infections / drug therapy*

Substances

  • Acetamides
  • Anti-Bacterial Agents
  • Oxazolidinones
  • Aminopeptidases
  • Amidohydrolases
  • peptide deformylase
  • Linezolid